Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
CA 2373239 A1 · Owner: Olbrich, Carsten · Inventors: Olbrich, Carsten; Muller, Rainer Helmut; Grubhofer, Nikolaus
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a stability and biocompatibility-optimized adjuvant (SBA) for enhancing the humoral and cellular immune response by jointly injecting said adjuvant with one or more antigens. The adjuvant consists of particles based on solid lipids or solid lipid mixtures and can be used in the production of more efficient and compatible vaccines the inoculation of human , beings and animals and for obtaining antibodies. The strength of the immune response can be modulated in a targeted manner and additionally adapted to the specific species by selecting the size charge and surface characteristics of the particles. Other adjuvants, e.g. molecular adjuvants such as GMDP can be …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 19, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 19, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 19, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.